系统型红斑狼疮的治疗新趋势——生物治疗  

Biological agents as a new therapeutic strategy for systemic lupus erythematosus

作　　者：田新平[1] 

机构地区：[1]中国协和医科大学北京协和医院风湿免疫科,北京100730

出　　处：《基础医学与临床》2005年第9期769-773,共5页Basic and Clinical Medicine

摘　　要：系统型红斑狼疮(SLE)的治疗极具挑战性。传统的免疫抑制治疗虽然可以缓解病情,但继发感染和药物毒性限制了其临床应用。针对SLE发病机制中某一环节的特异生物治疗已成为近年来SLE治疗方面的主要进展。目前的生物治疗主要包括改变细胞因子活化和调节、抑制T细胞活化并诱导T细胞耐受、阻断T-B细胞相互作用、作用于B细胞以减少B细胞产生抗dsDNA抗体、抑制补体活化、基因治疗和造血干细胞移植。但生物治疗在SLE治疗中的地位和安全性尚需大规模、长期临床试验来确定。The treatment of systemic lupus erythematosus（SLE） is a significant therapeutic challenge. The efficacy of classical immunosuppressents was limited by their toxicities and secondary infections. Biological agents designed to specifically interfere with the pathogenesis have become the new advance in SLE treatment. The biological agents recently developed can be divided into the following categories： alternating cytokine activation and modulation, inhibiting T cell activation and T-B cell collaboration, depleting B cells in order to interfere with the production of anti-double-stranded DNA antibodies, inhibiting complement activation, gene therapy and hematopoietic stem cell transplantation. However, the efficacy and safety of biological agents in SLE treatment needs to be further identified by long-term, large-scale clinical trials.

关 键 词：系统型 红斑狼疮 生物制剂 

分 类 号：R593.241[医药卫生—内科学]